Literature DB >> 16628418

Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.

Ariko Kojima1, Kyoko Ohno-Matsui, Satoshi Teramukai, Yoko Ishihara, Noriaki Shimada, Takeshi Yoshida, Yoshiharu Sugamoto, Takashi Tokoro, Manabu Mochizuki.   

Abstract

OBJECTIVE: To clarify prognostic factors of long-term visual outcome without treatment in patients with myopic choroidal neovascularization (CNV) and estimate a regression equation to predict visual acuity at 5 years after CNV onset.
METHODS: Fifty-four eyes of 54 consecutive patients with high myopia and subfoveal CNV who did not receive treatment were identified using clinical records from 1988 to 2004. Photodynamic therapy not approved for myopic CNV in Japan during this period. The association of best-corrected visual acuity (BCVA) at 5 years after CNV onset with patient age, refractive error, axial length, initial BCVA, myopic retinopathy grade, duration of persistent hemorrhage, CNV size at onset, and size of hemorrhage around the CNV was analyzed using Spearman's correlation and multiple linear regression analysis.
RESULTS: BCVA at 5 years after onset was significantly associated with patient age, CNV size, and initial BCVA (P<0.05, Spearman's correlation). The regression equation estimating BCVA at 5 years after CNV onset was based on age and initial BCVA (R2=0.43). When subjects were divided into groups according to age (<40 and >or=40 years), CNV size, axial length and duration of persistent hemorrhage influenced BCVA at 5 years in patients under 40 years; while only initial BCVA was an influence in those at least 40 years old.
CONCLUSIONS: We developed a linear predictive model to estimate BCVA at 5 years after onset of myopic CNV without treatment based on the identified prognostic factors. This information might be important for managing patients with myopic CNV.

Entities:  

Mesh:

Year:  2006        PMID: 16628418     DOI: 10.1007/s00417-006-0324-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  22 in total

1.  Macular complications associated with posterior staphyloma.

Authors:  S M Steidl; R C Pruett
Journal:  Am J Ophthalmol       Date:  1997-02       Impact factor: 5.258

2.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

3.  [Investigation of the vitreo-retino-ciliary barrier by vitreous fluorophotometry. 5. Alteration of the inward permeability of the blood-retinal barrier and the diffusion coefficient of fluorescein in the vitreous with aging in normal subjects].

Authors:  A Yoshida; K Murakami; M Kojima
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1986-04

4.  Pathologic myopia and choroidal neovascularization.

Authors:  M L Hotchkiss; S L Fine
Journal:  Am J Ophthalmol       Date:  1981-02       Impact factor: 5.258

5.  On the definition of pathologic myopia in group studies.

Authors:  T Tokoro
Journal:  Acta Ophthalmol Suppl       Date:  1988

6.  Myopic choroidal neovascularization: a 10-year follow-up.

Authors:  Takeshi Yoshida; Kyoko Ohno-Matsui; Kenjiro Yasuzumi; Ariko Kojima; Noriaki Shimada; Soh Futagami; Takashi Tokoro; Manabu Mochizuki
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

7.  Visual prognosis of disciform degeneration in myopia.

Authors:  G R Hampton; D Kohen; A C Bird
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

8.  Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

9.  Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Erdem Ergun; Harald Heinzl; Michael Stur
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258

10.  Prevalence of myopia in the United States.

Authors:  R D Sperduto; D Seigel; J Roberts; M Rowland
Journal:  Arch Ophthalmol       Date:  1983-03
View more
  9 in total

1.  Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.

Authors:  Tugrul Altan; Nur Acar; Ziya Kapran; Yaprak B Unver; Sezin Ozdogan
Journal:  Int Ophthalmol       Date:  2012-02-19       Impact factor: 2.031

2.  Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.

Authors:  P J Rosenfeld
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

3.  Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study.

Authors:  Ming-Chin Yang; Yen-Po Chen; Elise Chia-Hui Tan; Claudia Leteneux; Erin Chang; Carol Hy Chu; Chi-Chun Lai
Journal:  Jpn J Ophthalmol       Date:  2017-01-06       Impact factor: 2.447

4.  Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

Authors:  Bogomil Voykov; Faik Gelisken; Werner Inhoffen; Michael Voelker; Karl Ulrich Bartz-Schmidt; Focke Ziemssen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-01-29       Impact factor: 3.117

5.  Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization.

Authors:  H Nakanishi; A Tsujikawa; Y Yodoi; Y Ojima; A Otani; H Tamura; K Yamashiro; S Ooto; N Yoshimura
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

6.  Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization.

Authors:  Jane Zea-Chin Kuo; Frank Shih-Chang Ong; Ling Yeung; Wei-Chi Wu; Yen-Po Chen; Nan-Kai Wang; Chi-Chun Lai
Journal:  Retina       Date:  2011-10       Impact factor: 4.256

7.  The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization.

Authors:  Buğra Karasu; Ali Rıza Cenk Celebi
Journal:  Int Ophthalmol       Date:  2022-03-31       Impact factor: 2.029

Review 8.  Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.

Authors:  Kelvin Yi Chong Teo; Wei Yan Ng; Shu Yen Lee; Chui Ming Gemmy Cheung
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 9.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.